Advertisement

Topics

Top five promising drugs Phase II (November 2013)

23:33 EDT 20th September 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE II TRIALS

Drug Disease Company
Sel-G1 Sickle cell anemia Selexys Pharmaceuticals
NSI-566 Amyotrophic lateral sclerosis Neuralstem
EB-1020 Attention deficit hyperactivity disorder Euthymics Bioscience / Neurovance
CAT-2003 Hyperlipidemia Catabasis Pharmaceuticals
THR-184 Acute kidney injury Thrasos Therapeutics

Source: Thomson Reuters Cortellis Competitive Intelligence.

Quick Search
Advertisement
 

review and buy Top five promising drugs Phase II (November 2013) market research data and corporate reports here